Daniel O'Day to lead Roche Pharma as Pascal Soriot moves to AstraZeneca

Daniel O'Day.

Daniel O’Day, the former president and CEO of Roche Molecular Diagnostics in Pleasanton, will become chief operating officer of Roche Pharma as Pascal Soriot, who oversaw the tricky integration of Genentech Inc. into Roche, takes the helm of rival drug maker AstraZeneca. O’Day’s appointment is an important one, underscoring the Swiss drug maker’s commitment to developing companion diagnostics for its drugs. As COO of Roche Diagnostics since 2010, he has been a member of Roche’s executive committee. Roche CEO Severin Schwan noted in a press release late Monday night that O’Day has “a very impressive track record” in diagnostics and pharmaceuticals.

MedImmune will open new center, shift 40 jobs to Hayward

The South Bay's loss of MedImmune will be the East Bay's gain.

The vaccine and infectious diseases drug developer said it plans to open a new translational sciences area for applied immunology and microbiology in Hayward as it closes facilities in Mountain View and Santa Clara.

MedImmune to close Mountain View, Santa Clara, ax 300 jobs

MedImmune will close its Mountain View and Santa Clara sites as part of a plan to cut about 300 jobs.

About 100 jobs will move to other MedImmune facilities, including one in Hayward, the company said.